Loading…

Atorvastatin calcium loaded chitosan nanoparticles: in vitro evaluation and in vivo pharmacokinetic studies in rabbits

In this study, we prepared atorvastatin calcium (AVST) loaded chitosan nanoparticles to improve the oral bioavailability of the drug. Nanoparticles were prepared by solvent evaporation technique and evaluated for its particle size, entrapment efficiency, zeta potential, in vitro release and surface...

Full description

Saved in:
Bibliographic Details
Published in:Brazilian Journal of Pharmaceutical Sciences 2015-06, Vol.51 (2), p.467-477
Main Authors: Ahmed, Abdul Baquee, Konwar, Ranjit, Sengupta, Rupa
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c411t-ae0f4e1cbc67891613a91b5b0eee7f3ea5c2bb8d78659f6ec199a16d384779a73
cites cdi_FETCH-LOGICAL-c411t-ae0f4e1cbc67891613a91b5b0eee7f3ea5c2bb8d78659f6ec199a16d384779a73
container_end_page 477
container_issue 2
container_start_page 467
container_title Brazilian Journal of Pharmaceutical Sciences
container_volume 51
creator Ahmed, Abdul Baquee
Konwar, Ranjit
Sengupta, Rupa
description In this study, we prepared atorvastatin calcium (AVST) loaded chitosan nanoparticles to improve the oral bioavailability of the drug. Nanoparticles were prepared by solvent evaporation technique and evaluated for its particle size, entrapment efficiency, zeta potential, in vitro release and surface morphology by scanning electron microscopy (SEM). In addition, the pharmacokinetics of AVST from the optimized formulation (FT5) was compared with marketed immediate release formulation (Atorva(r)) in rabbits. Particle size of prepared nanoparticles was ranged between 179.3 ± 7.12 to 256.8 ± 8.24 nm with a low polydispersity index (PI) value. Zeta potential study showed that the particles are stable with positive values between 13.03 ± 0.32 to 46.90 ± 0.49 mV. FT-IR studies confirmed the absence of incompatibility of AVST with excipient used in the formulations. In vitro release study showed that the drug release was sustained for 48 h. Results of pharmacokinetics study showed significant changes in the pharmacokinetic parameter (2.2 fold increase in AUC) of the optimized formulation as compared to marketed formulation (Atorva(r)). Thus, the developed nanoparticles evidenced the improvement of oral bioavailability of AVST in rabbit model. No presente estudo, preparamos nanopartículas de quitosana com atorvastatina cálcica (AVST) para melhorar a biodisponibilidade oral do fármaco. As nanopartículas foram preparadas pela técnica de evaporação de solvente, avaliando-se a granulometria, a eficiência de encapsulamento, o potencial zeta, a liberação in vitroe a morfologia da superfície, por meio da microscopia eletrônica de varredura (MEV). Além disso, a farmacocinética da formulação otimizada de AVST (FT5) foi comparada com a formulação comercial, de liberação imediata, comercializada (Atorva(r)), em coelhos. O tamanho das das nanopartículas variou na faixa de 179,3 a 256,8 ± 7,12 ± 8,24 nm, com baixo índice polidispersibilidade (PI). O estudo do potencial Zeta mostrou que as partículas são estáveis, com valores positivos entre 13,03 ± 0,32 a 46,90 ± 0,49 mV. Os estudos de FT-IR confirmaram a ausência de incompatibilidade de AVST com o excipiente utilizado nas formulações. O estudo de liberação in vitro mostrou que liberação sustentada do fármaco por 48 horas. Os resultados do estudo farmacocinético mostraram alterações significativas nos parâmetros (aumento de 2,2 vezes na ASC) da formulação otimizada em relação à comercializada (Atorva(r) ). Assim, o desenvolviment
doi_str_mv 10.1590/S1984-82502015000200024
format article
fullrecord <record><control><sourceid>scielo_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_0c5910d9a7a7461fae3d63580bd54040</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><scielo_id>S1984_82502015000200467</scielo_id><doaj_id>oai_doaj_org_article_0c5910d9a7a7461fae3d63580bd54040</doaj_id><sourcerecordid>S1984_82502015000200467</sourcerecordid><originalsourceid>FETCH-LOGICAL-c411t-ae0f4e1cbc67891613a91b5b0eee7f3ea5c2bb8d78659f6ec199a16d384779a73</originalsourceid><addsrcrecordid>eNptkW9LwzAQxoMoOHSfwXyBzmRN2sZ3Y_hnMPCF-jpck9Rlds1I0oLf3mwdQ8EXxx1393ty4UHojpIZ5YLcv1FRsayaczInlBOSUgp2gSbnweWv-hpNQ9imFcpZJRifoGERnR8gRIi2wwpaZfsdbh1oo7Ha2OgCdLiDzu3BR6taEx5w2hxs9A6bAdo-ka7D0OmxPzi834DfgXJftjOJwSH22ppwmHuoaxvDLbpqoA1meso36OPp8X35kq1fn1fLxTpTjNKYgSENM1TVqigrQQuag6A1r4kxpmxyA1zN67rSZVVw0RRGUSGAFjqvWFkKKPMbtBp1tYOt3Hu7A_8tHVh5bDj_KU_fkkRxQYlOFJSsoA2YXBc5r0itOSOMJK3ZqBWUNa2TW9f7Lh0vjybIvyaw4vB4OQLKuxC8ac4HUCIP9v1LJvvyH4SNjQU</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Atorvastatin calcium loaded chitosan nanoparticles: in vitro evaluation and in vivo pharmacokinetic studies in rabbits</title><source>SciELO</source><creator>Ahmed, Abdul Baquee ; Konwar, Ranjit ; Sengupta, Rupa</creator><creatorcontrib>Ahmed, Abdul Baquee ; Konwar, Ranjit ; Sengupta, Rupa</creatorcontrib><description>In this study, we prepared atorvastatin calcium (AVST) loaded chitosan nanoparticles to improve the oral bioavailability of the drug. Nanoparticles were prepared by solvent evaporation technique and evaluated for its particle size, entrapment efficiency, zeta potential, in vitro release and surface morphology by scanning electron microscopy (SEM). In addition, the pharmacokinetics of AVST from the optimized formulation (FT5) was compared with marketed immediate release formulation (Atorva(r)) in rabbits. Particle size of prepared nanoparticles was ranged between 179.3 ± 7.12 to 256.8 ± 8.24 nm with a low polydispersity index (PI) value. Zeta potential study showed that the particles are stable with positive values between 13.03 ± 0.32 to 46.90 ± 0.49 mV. FT-IR studies confirmed the absence of incompatibility of AVST with excipient used in the formulations. In vitro release study showed that the drug release was sustained for 48 h. Results of pharmacokinetics study showed significant changes in the pharmacokinetic parameter (2.2 fold increase in AUC) of the optimized formulation as compared to marketed formulation (Atorva(r)). Thus, the developed nanoparticles evidenced the improvement of oral bioavailability of AVST in rabbit model. No presente estudo, preparamos nanopartículas de quitosana com atorvastatina cálcica (AVST) para melhorar a biodisponibilidade oral do fármaco. As nanopartículas foram preparadas pela técnica de evaporação de solvente, avaliando-se a granulometria, a eficiência de encapsulamento, o potencial zeta, a liberação in vitroe a morfologia da superfície, por meio da microscopia eletrônica de varredura (MEV). Além disso, a farmacocinética da formulação otimizada de AVST (FT5) foi comparada com a formulação comercial, de liberação imediata, comercializada (Atorva(r)), em coelhos. O tamanho das das nanopartículas variou na faixa de 179,3 a 256,8 ± 7,12 ± 8,24 nm, com baixo índice polidispersibilidade (PI). O estudo do potencial Zeta mostrou que as partículas são estáveis, com valores positivos entre 13,03 ± 0,32 a 46,90 ± 0,49 mV. Os estudos de FT-IR confirmaram a ausência de incompatibilidade de AVST com o excipiente utilizado nas formulações. O estudo de liberação in vitro mostrou que liberação sustentada do fármaco por 48 horas. Os resultados do estudo farmacocinético mostraram alterações significativas nos parâmetros (aumento de 2,2 vezes na ASC) da formulação otimizada em relação à comercializada (Atorva(r) ). Assim, o desenvolvimento de nanopartículas evidenciou a melhora da biodisponibilidade oral de AVST em coelhos.</description><identifier>ISSN: 1984-8250</identifier><identifier>ISSN: 2175-9790</identifier><identifier>EISSN: 1984-8250</identifier><identifier>DOI: 10.1590/S1984-82502015000200024</identifier><language>eng</language><publisher>Universidade de São Paulo, Faculdade de Ciências Farmacêuticas</publisher><subject>Atorvastatina cálcica/biodisponibilidade oral/estudo experimental ; Atorvastatina cálcica/farmacocinética ; Atorvastatina cálcica/liberação in vitro ; Nanopartículas/biodisponibilidade de fármacos ; PHARMACOLOGY &amp; PHARMACY</subject><ispartof>Brazilian Journal of Pharmaceutical Sciences, 2015-06, Vol.51 (2), p.467-477</ispartof><rights>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c411t-ae0f4e1cbc67891613a91b5b0eee7f3ea5c2bb8d78659f6ec199a16d384779a73</citedby><cites>FETCH-LOGICAL-c411t-ae0f4e1cbc67891613a91b5b0eee7f3ea5c2bb8d78659f6ec199a16d384779a73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,24148,27922,27923</link.rule.ids></links><search><creatorcontrib>Ahmed, Abdul Baquee</creatorcontrib><creatorcontrib>Konwar, Ranjit</creatorcontrib><creatorcontrib>Sengupta, Rupa</creatorcontrib><title>Atorvastatin calcium loaded chitosan nanoparticles: in vitro evaluation and in vivo pharmacokinetic studies in rabbits</title><title>Brazilian Journal of Pharmaceutical Sciences</title><addtitle>Braz. J. Pharm. Sci</addtitle><description>In this study, we prepared atorvastatin calcium (AVST) loaded chitosan nanoparticles to improve the oral bioavailability of the drug. Nanoparticles were prepared by solvent evaporation technique and evaluated for its particle size, entrapment efficiency, zeta potential, in vitro release and surface morphology by scanning electron microscopy (SEM). In addition, the pharmacokinetics of AVST from the optimized formulation (FT5) was compared with marketed immediate release formulation (Atorva(r)) in rabbits. Particle size of prepared nanoparticles was ranged between 179.3 ± 7.12 to 256.8 ± 8.24 nm with a low polydispersity index (PI) value. Zeta potential study showed that the particles are stable with positive values between 13.03 ± 0.32 to 46.90 ± 0.49 mV. FT-IR studies confirmed the absence of incompatibility of AVST with excipient used in the formulations. In vitro release study showed that the drug release was sustained for 48 h. Results of pharmacokinetics study showed significant changes in the pharmacokinetic parameter (2.2 fold increase in AUC) of the optimized formulation as compared to marketed formulation (Atorva(r)). Thus, the developed nanoparticles evidenced the improvement of oral bioavailability of AVST in rabbit model. No presente estudo, preparamos nanopartículas de quitosana com atorvastatina cálcica (AVST) para melhorar a biodisponibilidade oral do fármaco. As nanopartículas foram preparadas pela técnica de evaporação de solvente, avaliando-se a granulometria, a eficiência de encapsulamento, o potencial zeta, a liberação in vitroe a morfologia da superfície, por meio da microscopia eletrônica de varredura (MEV). Além disso, a farmacocinética da formulação otimizada de AVST (FT5) foi comparada com a formulação comercial, de liberação imediata, comercializada (Atorva(r)), em coelhos. O tamanho das das nanopartículas variou na faixa de 179,3 a 256,8 ± 7,12 ± 8,24 nm, com baixo índice polidispersibilidade (PI). O estudo do potencial Zeta mostrou que as partículas são estáveis, com valores positivos entre 13,03 ± 0,32 a 46,90 ± 0,49 mV. Os estudos de FT-IR confirmaram a ausência de incompatibilidade de AVST com o excipiente utilizado nas formulações. O estudo de liberação in vitro mostrou que liberação sustentada do fármaco por 48 horas. Os resultados do estudo farmacocinético mostraram alterações significativas nos parâmetros (aumento de 2,2 vezes na ASC) da formulação otimizada em relação à comercializada (Atorva(r) ). Assim, o desenvolvimento de nanopartículas evidenciou a melhora da biodisponibilidade oral de AVST em coelhos.</description><subject>Atorvastatina cálcica/biodisponibilidade oral/estudo experimental</subject><subject>Atorvastatina cálcica/farmacocinética</subject><subject>Atorvastatina cálcica/liberação in vitro</subject><subject>Nanopartículas/biodisponibilidade de fármacos</subject><subject>PHARMACOLOGY &amp; PHARMACY</subject><issn>1984-8250</issn><issn>2175-9790</issn><issn>1984-8250</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNptkW9LwzAQxoMoOHSfwXyBzmRN2sZ3Y_hnMPCF-jpck9Rlds1I0oLf3mwdQ8EXxx1393ty4UHojpIZ5YLcv1FRsayaczInlBOSUgp2gSbnweWv-hpNQ9imFcpZJRifoGERnR8gRIi2wwpaZfsdbh1oo7Ha2OgCdLiDzu3BR6taEx5w2hxs9A6bAdo-ka7D0OmxPzi834DfgXJftjOJwSH22ppwmHuoaxvDLbpqoA1meso36OPp8X35kq1fn1fLxTpTjNKYgSENM1TVqigrQQuag6A1r4kxpmxyA1zN67rSZVVw0RRGUSGAFjqvWFkKKPMbtBp1tYOt3Hu7A_8tHVh5bDj_KU_fkkRxQYlOFJSsoA2YXBc5r0itOSOMJK3ZqBWUNa2TW9f7Lh0vjybIvyaw4vB4OQLKuxC8ac4HUCIP9v1LJvvyH4SNjQU</recordid><startdate>20150601</startdate><enddate>20150601</enddate><creator>Ahmed, Abdul Baquee</creator><creator>Konwar, Ranjit</creator><creator>Sengupta, Rupa</creator><general>Universidade de São Paulo, Faculdade de Ciências Farmacêuticas</general><general>Universidade de São Paulo</general><scope>AAYXX</scope><scope>CITATION</scope><scope>GPN</scope><scope>DOA</scope></search><sort><creationdate>20150601</creationdate><title>Atorvastatin calcium loaded chitosan nanoparticles: in vitro evaluation and in vivo pharmacokinetic studies in rabbits</title><author>Ahmed, Abdul Baquee ; Konwar, Ranjit ; Sengupta, Rupa</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c411t-ae0f4e1cbc67891613a91b5b0eee7f3ea5c2bb8d78659f6ec199a16d384779a73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Atorvastatina cálcica/biodisponibilidade oral/estudo experimental</topic><topic>Atorvastatina cálcica/farmacocinética</topic><topic>Atorvastatina cálcica/liberação in vitro</topic><topic>Nanopartículas/biodisponibilidade de fármacos</topic><topic>PHARMACOLOGY &amp; PHARMACY</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ahmed, Abdul Baquee</creatorcontrib><creatorcontrib>Konwar, Ranjit</creatorcontrib><creatorcontrib>Sengupta, Rupa</creatorcontrib><collection>CrossRef</collection><collection>SciELO</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Brazilian Journal of Pharmaceutical Sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ahmed, Abdul Baquee</au><au>Konwar, Ranjit</au><au>Sengupta, Rupa</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Atorvastatin calcium loaded chitosan nanoparticles: in vitro evaluation and in vivo pharmacokinetic studies in rabbits</atitle><jtitle>Brazilian Journal of Pharmaceutical Sciences</jtitle><addtitle>Braz. J. Pharm. Sci</addtitle><date>2015-06-01</date><risdate>2015</risdate><volume>51</volume><issue>2</issue><spage>467</spage><epage>477</epage><pages>467-477</pages><issn>1984-8250</issn><issn>2175-9790</issn><eissn>1984-8250</eissn><abstract>In this study, we prepared atorvastatin calcium (AVST) loaded chitosan nanoparticles to improve the oral bioavailability of the drug. Nanoparticles were prepared by solvent evaporation technique and evaluated for its particle size, entrapment efficiency, zeta potential, in vitro release and surface morphology by scanning electron microscopy (SEM). In addition, the pharmacokinetics of AVST from the optimized formulation (FT5) was compared with marketed immediate release formulation (Atorva(r)) in rabbits. Particle size of prepared nanoparticles was ranged between 179.3 ± 7.12 to 256.8 ± 8.24 nm with a low polydispersity index (PI) value. Zeta potential study showed that the particles are stable with positive values between 13.03 ± 0.32 to 46.90 ± 0.49 mV. FT-IR studies confirmed the absence of incompatibility of AVST with excipient used in the formulations. In vitro release study showed that the drug release was sustained for 48 h. Results of pharmacokinetics study showed significant changes in the pharmacokinetic parameter (2.2 fold increase in AUC) of the optimized formulation as compared to marketed formulation (Atorva(r)). Thus, the developed nanoparticles evidenced the improvement of oral bioavailability of AVST in rabbit model. No presente estudo, preparamos nanopartículas de quitosana com atorvastatina cálcica (AVST) para melhorar a biodisponibilidade oral do fármaco. As nanopartículas foram preparadas pela técnica de evaporação de solvente, avaliando-se a granulometria, a eficiência de encapsulamento, o potencial zeta, a liberação in vitroe a morfologia da superfície, por meio da microscopia eletrônica de varredura (MEV). Além disso, a farmacocinética da formulação otimizada de AVST (FT5) foi comparada com a formulação comercial, de liberação imediata, comercializada (Atorva(r)), em coelhos. O tamanho das das nanopartículas variou na faixa de 179,3 a 256,8 ± 7,12 ± 8,24 nm, com baixo índice polidispersibilidade (PI). O estudo do potencial Zeta mostrou que as partículas são estáveis, com valores positivos entre 13,03 ± 0,32 a 46,90 ± 0,49 mV. Os estudos de FT-IR confirmaram a ausência de incompatibilidade de AVST com o excipiente utilizado nas formulações. O estudo de liberação in vitro mostrou que liberação sustentada do fármaco por 48 horas. Os resultados do estudo farmacocinético mostraram alterações significativas nos parâmetros (aumento de 2,2 vezes na ASC) da formulação otimizada em relação à comercializada (Atorva(r) ). Assim, o desenvolvimento de nanopartículas evidenciou a melhora da biodisponibilidade oral de AVST em coelhos.</abstract><pub>Universidade de São Paulo, Faculdade de Ciências Farmacêuticas</pub><doi>10.1590/S1984-82502015000200024</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1984-8250
ispartof Brazilian Journal of Pharmaceutical Sciences, 2015-06, Vol.51 (2), p.467-477
issn 1984-8250
2175-9790
1984-8250
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_0c5910d9a7a7461fae3d63580bd54040
source SciELO
subjects Atorvastatina cálcica/biodisponibilidade oral/estudo experimental
Atorvastatina cálcica/farmacocinética
Atorvastatina cálcica/liberação in vitro
Nanopartículas/biodisponibilidade de fármacos
PHARMACOLOGY & PHARMACY
title Atorvastatin calcium loaded chitosan nanoparticles: in vitro evaluation and in vivo pharmacokinetic studies in rabbits
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T00%3A17%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-scielo_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Atorvastatin%20calcium%20loaded%20chitosan%20nanoparticles:%20in%20vitro%20evaluation%20and%20in%20vivo%20pharmacokinetic%20studies%20in%20rabbits&rft.jtitle=Brazilian%20Journal%20of%20Pharmaceutical%20Sciences&rft.au=Ahmed,%20Abdul%20Baquee&rft.date=2015-06-01&rft.volume=51&rft.issue=2&rft.spage=467&rft.epage=477&rft.pages=467-477&rft.issn=1984-8250&rft.eissn=1984-8250&rft_id=info:doi/10.1590/S1984-82502015000200024&rft_dat=%3Cscielo_doaj_%3ES1984_82502015000200467%3C/scielo_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c411t-ae0f4e1cbc67891613a91b5b0eee7f3ea5c2bb8d78659f6ec199a16d384779a73%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rft_scielo_id=S1984_82502015000200467&rfr_iscdi=true